



Financial Tear Sheet

Corporate Profile

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial. A program targeting sensorineural hearing loss including age-related hearing loss is in preclinical development. Otonomy's proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.

Stock Performance

OTIC (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	\$3.30
Change (%)	0.00 (0.00%)
Volume	676,711
52 Week High	\$21.15
52 Week Low	\$3.15
Data as of 09/25/17 4:00 p.m. ET	



Data Provided by Thomson Reuters

Recent Headlines & Events

09/13/17 - 7:31 a.m.
[Otonomy Provides Business and Financial Update](#)

08/30/17 - 7:01 a.m.
[Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
09/05/17	4
08/30/17	8-K

Primary IR Contact

E-mail: ir@otonomy.com